Proefschrift

CHAPTER 2.2 74 REFERENCES 1. Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. JCO 2017;35:3737–3744. doi:10.1200/JCO.2017.73.7916. 2. Voors AA. Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?∗. JACC: Heart Failure 2020;8:369–371. doi:10.1016/j.jchf.2020.01.007. 3. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun 2018;11:156–164. doi:10.1016/j.conctc.2018.08.001. 4. Massie BM. Globalization of Clinical Trials. Journal of the American College of Cardiology 2011;58:923–924. doi:10.1016/j.jacc.2011.04.027. 5. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25–32. doi:10.1093/eurheartj/eht278. 6. Sidney S, Quesenberry CP, Jaffe MG, Sorel M, Go AS, Rana JS. Heterogeneity in national U.S. mortality trends within heart disease subgroups, 2000–2015. BMC Cardiovascular Disorders 2017;17:192. doi:10.1186/s12872-017-0630-2. 7. U.S. Food & Drug Administration. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products guidance for industry. Maryland: U.S Food & Drug Administration; 2019. 8. Baldi I, Lanera C, Berchialla P, Gregori D. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015. BMJ Open 2017;7:e013482. doi:10.1136/bmjopen-2016-013482. 9. Psotka MA, Latta F, Cani D, Fiuzat M, Sbolli M, Barnett S, et al. Publication Rates of Heart Failure Clinical Trials Remain Low. Journal of the American College of Cardiology 2020;75:3151–3161. doi:10.1016/j.jacc.2020.04.068. 10. Evans SR, Paraoan D, Perlmutter J, Raman SR, Sheehan JJ, Hallinan ZP. Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. Ther Innov Regul Sci 2021;55:545–552. doi:10.1007/s43441-020-00248-7. 11. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816–823. doi:10.1056/NEJMsb0803929. 12. Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF, Anker SD, et al. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev 2014;19:135–152. doi:10.1007/s10741-012-9361-8. 13. Clinical Trials Transformation Initiative. AACT Database. Clinical Trials Transformation Initiative 2016. https://www.ctti-clinicaltrials.org/aact-database (accessed June 3, 2019). 14. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov Results Database — Update and Key Issues. New England Journal of Medicine 2011;364:852–860. doi:10.1056/NEJMsa1012065. 15. Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Research 2004;32:D267–D270. doi:10.1093/nar/gkh061. 16. The Apache Software Foundation. Apache UIMA RutaTM Guide and Reference 2013. https://uima.apache.org/d/ruta-current/tools.ruta.book.html (accessed June 7, 2022). 17. Soysal E, Wang J, Jiang M, Wu Y, Pakhomov S, Liu H, et al. CLAMP - a toolkit for efficiently building customized clinical natural language processing pipelines. J Am Med Inform Assoc 2018;25:331– 336. doi:10.1093/jamia/ocx132. 18. Observational Health Data Sciences and Informatics. The Book of OHDSI. Observational Health Data Sciences and Informatics; 2021. 19. Melax Technologies, Inc. LANN. LANN 2022. https://lann.melaxtech.com/ (accessed June 7, 2022).

RkJQdWJsaXNoZXIy MjY0ODMw